GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Change In Receivables

Outlook Therapeutics (FRA:41O) Change In Receivables : €0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Change In Receivables?

Outlook Therapeutics's change in receivables for the quarter that ended in Mar. 2024 was €0.00 Mil. It means Outlook Therapeutics's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Outlook Therapeutics's change in receivables for the fiscal year that ended in Sep. 2023 was €0.00 Mil. It means Outlook Therapeutics's Accounts Receivable stayed the same from Sep. 2022 to Sep. 2023 .

Outlook Therapeutics's Accounts Receivable for the quarter that ended in Mar. 2024 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Outlook Therapeutics's liquidation value for the three months ended in Mar. 2024 was €-134.35 Mil.


Outlook Therapeutics Change In Receivables Historical Data

The historical data trend for Outlook Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Change In Receivables Chart

Outlook Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Outlook Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Outlook Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Outlook Therapeutics  (FRA:41O) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Outlook Therapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

2. In Ben Graham's calculation of liquidation value, Outlook Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Outlook Therapeutics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=43.451-177.804+0.75 * 0+0.5 * 0
=-134.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Outlook Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Outlook Therapeutics (FRA:41O) Business Description

Traded in Other Exchanges
Address
485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Outlook Therapeutics (FRA:41O) Headlines

No Headlines